Platinum-based anticancer agents: Innovative design strategies and biological perspectives

Medicinal Research Reviews

Volumn 23, Issue 5, 2003, Pages 633-655

  Ho, Yee Ping ^a   Au Yeung, Steve C F ^b   To, Kenneth K W ^a  

^a Prince of Wales Hospital   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anticancer agents; Demethylcantharidin; Platinum complexes; Protein phosphatase inhibition

Indexed keywords

1,2 DIAMINOCYCLOHEXANE; ALKALOID; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BLEOMYCIN; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DACTINOMYCIN; DEMETHYLCANTHARIDIN; DOXORUBICIN; FLUOROURACIL; FOLIC ACID ANTAGONIST; LIGAND; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PLATINUM COMPLEX; PLATINUM DERIVATIVE; PODOPHYLLOTOXIN; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TAXOID; TIOGUANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER THERAPY; DNA ADDUCT; DNA REPAIR; DRUG ACTIVITY; DRUG MECHANISM; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG STRUCTURE; MOLECULAR BIOLOGY; PROTEIN MODIFICATION; REVIEW; STRUCTURE ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG DESIGN; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MODELS, CHEMICAL; NEOPLASMS; PHOSPHOPROTEIN PHOSPHATASE; PLATINUM COMPOUNDS;

EID: 0041426460     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.10038     Document Type: Review

References (153)

1. Coggins PR, Ravdin RG, Eisman SH. Clinical Pharmacology and preliminary evaluation of cytoxan (cyclophosphamide). Cancer Chemother Rep 1959;3:9-11.
2. Rege VB, Owens AH, Jr. BCNU (NSC-409962) in the treatment of advanced Hodgkin's disease, lymphosarcoma, and reticulum cell sarcoma. Cancer Chemother Rep 1974;58:383-392.
3. Haddow A, Timmis GM. Myleran in chronic myeloid leukemia: Chemical constitution and biological action. Lancet 1953;264:207-208.
4. Einhorn LH, Donohue JP. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977;87:293-298.
5. Wang JJ, Freeman AI, Sinks LF. Treatment of acute lymphocytic leukemia by high-dose intravenous methotrexate. Cancer Res 1976;36:1441-1444.
6. Gupta S. Treatment of advanced gastric cancer with 5-fluorouracil versus mitomycin C. J Surg Oncol 1982;21:94-96.
7. Lyman MS, Burchenal JH. Acute leukemia. Am J Nurs 1963;63:82-86.
8. Booser DJ, Hortobagyi GN. Anthracyclin antibiotics in cancer therapy. Drugs 1994;47:223-258.
9. Miyamoto T. Antitumor effects and pulmonary toxicity of bleomycin administered by continuous subcutaneous infusion in patients with advanced cervical cancer. Jpn J Cancer Chemother 1987;14:1830-1835.
10. De Camargo B, Franco EL. Single-dose versus fractionated-dose dactinomycin in the treatment of Wilms' tumor: Preliminary results of a clinical trial. The Brazilian Wilms' Tumor Study Group. Cancer 1991;67:2990-2996.
11. Arcangeli G, Zaniboni A, Milano S, Meriggi F, Simoncini E, Marpicati P, Marini G. MICE: A new active combination for non-small cell lung cancer. Eur J Cancer 1993;29A:1848-1850.
12. Morgan DA, Gilson D, Fletcher J. Vincristine and etoposide: An effective chemotherapy regimen with reduced toxicity in extensive small-cell lung cancer. Eur J Cancer Clin Oncol 1987;23:619-621.
13. Belani CP, Doyle LA, Aisner J. Etoposide: Current status and future perspectives in the management of malignant neoplasms. Cancer Chemother Pharmacol 1994;34:118-126.
14. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82:1247-1259.
15. Burris H, Irvin R, Kuhn JG, Von Hoff DD. Clinical trials with the topoisomerase I inhibitors. Semin Oncol 1992;19:663-669.
16. Fisher B. The evolution of paradigms for the management of breast cancer: A personal perspective. Cancer Res 1992;52:2371-2383.
17. Bergan RC, Reed E, Myers CE, Headlee D, Brawley O, Cho H-K, Figg WD, Tompkins A, Linehan WM, Kohler D, Steinberg SM, Blagosklonny MV. A phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin Cancer Res 1999;5:2366-2373.
18. Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965;205:698-699.
19. Rosenberg B, Van Camp L, Trosko JE, Mansour VH. Platinum compounds: A new class of potent antitumor agents. Nature 1969;222:385-386.
20. Ash DC. Cis-platinum (II) diamminedichloride: Clinical review of a new cancer chemotherapeutic agent. J Clin Hemat Oncol 1980;10:55-62.
21. Chu G. Cellular responses to cisplatin: The roles of DNA binding proteins and DNA repair. J Biol Chem 1994;269:787-790.
22. Rosenberg B. Platinum complexes for the treatment of cancer: Why the search goes on. In: Lippert B, editor. Chemistry and biochemistry of a leading anticancer drug. New York: Wiley-VCH; 1999. p 1-27.
23. Schaefer SD, Post JD, Close LG, Wright CG. Ototoxicity of low- and moderate-dose cisplatin. Cancer 1985;56:1934-1939.
24. Goren MP, Wright RK, Horowitz ME. Cumulative renal tubular damage associated with cisplatin nephrotoxicity. Cancer Chemother Pharmacol 1986;18:69-73.
25. Alberts DS, Noel JK. Cisplatin-associated neurotoxicity: Can it be prevented? Anticancer Drugs 1995;6:369-383.
26. Pera MF, Zook BC, Harder HC. Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammineplatinum(II) in rats. Cancer Res 1979;39:1269-1278.
27. Ozols RF, Corden BJ, Collins J, Young RC. In: Hacker PM, Douple E, Krakoff HI, editors. Platinum coordination complexes in cancer chemotherapy. Boston: Martinus-Nijhoff Publishers; 1984. p 321-329.
28. Ozols RF, Corden RJ, Isash J, Wesley MN, Otschaga Y, Young RC. High-dose cisplatin in hypertonic saline. Ann Intern Med 1984;100:19-24.
29. Borch RF, Bedon PC, Gringeri A, Montine TJ. In: Nicolini M, editor. Platinum and other metal coordination compounds in cancer chemotherapy. Boston: Martinus-Nijhoff; 1988. p 207-215.
30. Perez RP, Hamilton TC, Ozols RF, Young RC. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer 1993;71:1571-1580.
31. Ozols RF. Ovarian cancer: New clinical approaches. Cancer Treat Rev 1991;18:77-83.
32. Ozols RF. Chemotherapy for advanced epithelial ovarian cancer. Hematol Oncol Clin North Am 1992;6:879-894.
33. Douple EB. Cis-diamminedichloroplatinum(II): Effects of a representative metal coordination complex on mammalian cells. Pharmac Ther 1984;25:297-326.
34. Eastman A, Schulte N, Sheibani N, Sorenson CM. Mechanisms of resistance to platinum drugs. In: Nicolini M, editor. Platinum and other metal coordination compounds in cancer chemotherapy. Boston: Martinus Nijhoff Publishing; 1988. p 178-196.
35. Reedijk J, Fichtinger-Schepmann AMJ, van Oosterom AT, van de Putte P. Platinum amine coordination compounds as anti-tumor drugs: Molecular aspects of the mechanism of action. Structure Bonding 1987;67:53-89.
36. Sherman SE, Lippard SJ. Stuctural aspects of platinum anticancer drug interactions with DNA. Chem Rev 1987;87:1153-1181.
37. Hambley TW. Platinum binding to DNA: Structural controls and consequences. J Chem Soc Dalton Trans 2001:2711-2718.
38. Sorenson CM, Eastman A. Mechanism of cis-diammunedichloroplatinum(II)-induced cytotoxicity: Role of G2 arrest and DNA double-strand breaks. Cancer Res 1988;48:4484-4488.
39. L can differentially block chemotherapy-induced cell death. Blood 1997;90:1208-1216.
40. Eastman A. The mechanism of action of cisplatin: From adducts to apoptosis. In: Lippert B, editor. Cisplatin, chemistry and biochemistry of a leading anticancer drug. Basel: Wiley-VCH; 1999. p 111-134.
41. Wyllie AH, Kerr JFR, Currie AR. Cell death: The significance of apoptosis. Int Rev Cytol 1980;68:251-307.
42. Searle J, Kerr JFR, Bishop CL. Necrosis and apoptosis: Distinct modes of cell death with fundamentally different significance. Pathol Annu 1982;17:229-259.
43. Hickman JA. Apoptosis induced by anticancer agents. Cancer Metastasis Rev 1992;11:121-139.
44. Dive C, Wyllie AH. Apoptosis and cancer chemotherapy. In: Hickman JA, Tritton TR, editors. Frontiers in pharmacology. Oxford: Blackwell Scientific Press; 1993. p 21-56.
45. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998;24:331-344.
46. Mu D, Shu DS, Sancar A. Reaction mechanism of human DNA repair exision nuclease. J Biol Chem 1996;271:8285-8294.
47. Yamada M, O'Regan E, Brown R, Karrap P. Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucleic Acids Res 1997;25:491-495.
48. Reed E. Cisplatin. In: Pinedo HM, Longo DL, Chabner BA, editors. Cancer chemotherapy and biological response modifiers. BV Amsterdam: Elseiver Science; 1999. p 144-151.
49. Turchi JJ, Henkels K. Human aKU autoantigen binds cisplatin-damaged DNA but fails to stimulate human DNA-activated protein kinase. J Biol Chem 1996;271:13861-13867.
50. Henkels KM, Turchi JJ. Induction of apoptosis in cisplatin-sensitive and -resistant human ovarian cancer cell lines. Cancer Res 1997;57:4488-4492.
51. Zamble DB, Lippard SJ. The response of cellular proteins to cisplatin-damaged DNA. In: Lippert B, editor. Cisplatin, chemistry and biochemistry of a leading anticancer drug. Basel: Wiley-VCH; 1999. p 74-110.
52. Hughes EN, Engelsberg BN, Billings PC. Purification of nuclear proteins that bind to cisplatin-damaged DNA: Identity with high mobility group proteins I and 2. J Biol Chem 1992;267:13520-13527.
53. Slamon DJ, Godolphin W, Jones LA. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
54. Treiber DK, Zhai X, Jantzen H.-M, Essigmann JM. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human Upstream Binding Factor). Proc Natl Acad Sci USA 1994;91:5672-5676.
55. Jamieson ER, Lippard SJ. Structure, recognition and processing of cisplatin-DNA adducts. Chem Rev 1999;99:2467-2498.
56. Huang JC, Zamble DB, Reardon JT, Lippard SJ, Sancar A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA 1994;91:10394-10398.
57. Loehrer PJ, Einhom LH. Cisplatin. Annu Intern Med 1984;100:704-713.
58. Giaccone G. Clinical perspectives on platinum resistance. Drugs 2000;59:9-17.
59. Wolf CR, Hayward IP, Lawrie SS, Buckton K, McIntyre MA, Adams DJ, Lewis AD, Scott ARR, Smyth JF. Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int J Cancer 1987;39:696-701.
60. Johnson SW, Shen D-W, Pastan I, Gottesman MM, Hamilton TC. Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines. Exp Cell Res 1996;226:133-239.
61. Akiyama S-I, Chen Z-S, Sumizawa T, Furukawa T. Resistance to cisplatin. Anticancer Drug Des 1999;14:143-151.
62. Kelland LR. Preclinical perspectives on platinum resistance. Drugs 2000;59:1-8.
63. Andrews PA, Howell SB. Cellular pharmacology of cisplatin: Perspectives on mechanisms of acquired resistance. Cancer Cells 1990;2:35-43.
64. Mistry P, Kelland LR, Abel G. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 1991;64:215-220.
65. Chaney SG, Vaisman A. Specificity of platinum-DNA adduct repair. J Inorg Biochem 1999;77:71-81.
66. Rosenberg B, Van Camp L, Grimley EB, Thomas AJ. The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum (IV) complexes. J Biol Chem 1967;242:1347-1352.
67. Cleare MJ, Hoeschele JD. Studies on the antitumor activity of Group VIII transition metal complexes. Part 1. Platinum II complexes. Bioinorg Chem 1973;77:187-195.
68. Weiss RB, Christian MC. New cisplatin analogues in development. A review. Drugs 1993;46:360-377.
69. Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: A historical perspective and an update. Eur J Cancer 1998;34:1522-1534.
70. Wong E, Giandomenico CM. Current status of platinum-based antitumor drugs. Chem Rev 1999;99:2451-2466.
71. Macquet JP, Butour JL. Platinum-amine compounds: Importance of the labile and inert ligands for their pharmacological activities toward L1210 leukemia cells. J Natl Cancer Inst 1983;70:899-905.
72. Knox RJ, Friedlos F, Lydall DA, Roberts JJ. Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 1986;46:1972-1979.
73. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, NcElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KP. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum(II). Cancer Chemother Pharmacol 1982;9:140-147.
74. Evans BD, Raju KS, Calvert AH, Harland SJ, Wiltshaw E. JM8 (cis-diammine-1,1-cyclobutane dicarboxylate platinum II), a new platinum analogue active in the treatment of advanced ovarian carcinoma. Cancer Treat Rep 1983;67:997-1000.
75. Ruckdeschel JC. The future role of carboplatin. Semin Oncol 1994;21:114-118.
76. Harrap KR. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 1985;12:21-33.
77. Rixe O, Ortuzar W, Alvarez M. Oxaliplatin, Tetraplatin, Cisplatin and Carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem Pharmacol 1996;52:1855-1865.
78. Bitha P, Carvajal SG, Citarella RV, Child RG, Delos Santos EF, Dunne TS, Durr FE, Hlavka JJ, Lang SA, Jr. Lindsay HL, et al. Water-soluble third generation antitumor platinum complexes, [2,2-bis(aminomethyl)-1,2-propanediol-N,N′]-[1, 1-cyclobutane-dicarboxylato(2-)-O, O′]platinum(II) and [1,1-cyclobutanedicarboxylato(2-)-O,O′1-[tetrahydro-4H-pyran-4, 4-dimethanamine-N,N′]platinum(II). J Med Chem 1989;32(8):2015-2020.
79. Connors TA, Jones M, Ross WC, Braddock PD, Khokhar AR, Lobe ML. New platinum complexes with anti-tumor activity. Chem Biol Interact 1972;5:415-424.
80. Burchenal JH, Kalaher K, O'Toole T, Chisholm J. Lack of cross-resistance between certain platinum coordination compounds in mouse leukaemia. Cancer Res 1977;37:2455-2457.
81. Burchenal JH, Kalaher K, Lokys L. Studies of cross-resistance, synergistic combinations and blocking of activity of platinum derivatives. Biochimie 1978;60:961-965.
82. Burchenal JH, Kalaher K, Dew K, Lokys L. Rationale for development of platinum analogs. Cancer Treat Rep 1979;63:1493-1498.
83. Perez RP, Perez KM, Handel LM, Hamilton TC. In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines. Cancer Chemother Pharmacol 1992;29:430-434.
84. Jones M, Siracky J, Kelland LR, Harrap KR. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts. Br J Cancer 1993;67:24-29.
85. Tashiro T, Kawada Y, Sakurai Y. Antitumor activity of a new platinum complex, oxalato(trans-L-1,2-diaminocyclohexane)platinum(II): New experimental data. Biomed Pharmacother 1989;43:251-260.
86. Raymond E, Faivre S, Woynarowski JM. Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 1998;25:4-12.
87. Raymond E, Chaney SG, Taamma A. Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 1998;9:1053-1071.
88. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002;1:227-235.
89. Fink D, Nebel S, Aebi S. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-4886.
90. Fink D, Zheng H, Nebel S. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997;57:1841-1845.
91. Vaisman A, Varchenko M, Umar A. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998;58:3579-3585.
92. Hoeschele JD, Showalter HDH, Kraker AJ, Elliott WL, Roberts BJ, Kampf JW. Synthesis, structural characterization, and antitumor properties of a novel class of large-ring platinum(II) chelate complexes incorporating the cis- 1,4-diaminocyclohexane ligand in a unique locked boat conformation. J Med Chem 1994;37:2630-2636.
93. Hospers GAP, Mulder NH, de Jong B, de Ley L, Uges DRA, Fichtinger-Schepmann AMJ, Scheper RJ, de Vries EGE. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloro platinum(II) in vitro. Cancer Res 1988;48:6803-6807.
94. Teicher BA, Holden SA, Herman TS, Stomayor BA, Khandekar V, Rosbe KW, Brann TW, Korbutt TT, Frei E, III. Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II). Int J Cancer 1991;47:252-260.
95. Mellish KJ, Kelland LR, Harrap KR. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 1993;68:240-250.
96. Hasegawa Y, Morita M. Antitumor effect of oral cisplatin on certain murine tumors. Chem Pharm Bull 1985;33:5511-5514.
97. Van Hennik MB, Van der Vijgh WJF, Klein I, Vermoken JB, Pinedo HM. Human pharmacokinetics or carboplatin after oral administration. Cancer Chemother Pharmacol 1989;23:126-127.
98. Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR. Preclinical antitumor evaluation of bis-acetatoamminedichloro-cyclohexylamine Platinum(IV): An orally active platinum drug. Cancer Res 1993;53:2581-2586.
99. Rose WC, Crosswell AR, Schruig JE, Casazza AM. Preclinical antitumor activity of orally administered platinum (IV) complexes. Cancer Chemother Pharmacol 1993;32:197-203.
100. McKeage MJ, Raynaud F, Ward J, Berry C, O'Dell D, Kelland LR, Murrer B, Santabarabara P, Harrap KR, Judson IR. Phase I and pharmacokinetic study of an oral pltinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997;15:2691-2700.
101. Judson I, Cerny T, Epelbaum R, Dunlop D, Smyth J, Schaefer B, Roelvink M, Kaplan S, Hanauske A. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigation. Ann Oncol 1997;8:604-606.
102. Anon X. Satraplatin. Drugs Res Dev 2002;3(1):67-71.
103. Kelland LR, Murrer BA, Abei G, Giandomenico CM, Mistry P, Harrap KR. Ammine/amine platinum (IV) dicarboxylates: A novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 1992;52:822-828.
104. Harrap KR. Initiatives with platinum and quinazoline-based antitumor molecules. Cancer Res 1995;55:2761-2768.
105. Farrell N, Qu Y, Hacker MP. Cytotoxicity and antitumor activity of bis(platinum) complexes. A novel class of platinum complexes active in cell lines resistant to both cisplatin and 1,2-diaminocyclohexane complexes. J Med Chem 1990;33:2179-2184.
106. Farrell N. Nonclassical platinum antitumour agents: Perspectives for design and development of new drugs complementary to cisplatin. Cancer Invest 1993;11:578-589.
107. Farrell N, Appleton TG, Au Y, Roberts JD, Soares Fontes AP, Skov KA, Wu P, Zou Y. Effects of geometric isomerism and ligand substitution in bifunctional dinuclear platinum complexes on binding properties and conformational changes in DNA. Biochemistry 1995;34:15480-15486.
108. Di Blasi P, Bernareggi A, Beggiolin G, Piazzoni L, Menta E, Formento ML. Cytotoxicity, cellular uptake and DNA binding of the novel trinuclear platinum complex BBR 3464 in sensitive and cisplatin resistant murine leukemia cells. Anticancer Res 1998;18:3113-3118.
109. Perego P, Gatti L, Caserini C, Supino R, Colangelo D, Leon R, Spinelli S, Farrell N, Zunino F. The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells. J Inorg Biochem 1999;77:59-64.
110. Perego P, Caserini C, Gatti L, Carenini N, Romanelli S, Supino R, Colangelo D, Viano L, Leone R, Spinelli S, Pezzoni G, Mazotti C, Farrell N, Znino F. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol Pharm 1999;55:528-534.
111. Farrell N, Spindelli S. In: Farrell N, editor. Uses of inorganic chemistry in medicine. Cambridge: The Royal Society of Chemistry; 1999. p 124-134.
112. Wu PK, Kharatishvili M, Qu Y, Farrell N. A circular dichroism study of ethidium bromide binding to Z-DNA induced by dinuclear platinum complexes. J Inorg Biochem 1996;63:9-18.
113. Zou Y, Van Houten YB, Farrell N. Sequence specificity of DNA-DNA interstrand cross-link formation by cisplatin and dinuclear platinum complexes. Biochemistry 1994;33:5404-5410.
114. Versantvoort CHM, Broxterman HJ, Bagrij TR, Scheper J, Twentyman PR. Regulation by glutathione of drug transport in multidrug-resistant human lung tumor cell lines overexpressing multidrug resistance-associated protein. Br J Cancer 1995;72:82-89.
115. Pendyala L, Creaven PJ, Perez R, Zdanowicz JR, Raghavan D. Intracellular glutathione and cytotoxicity of platinum complexes. Cancer Chemother Pharmacol 1995;36:271-278.
116. Lai GM, Ozols RF, Young RC, Hamilton TC. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J Natl Cancer Inst 1989;81:535-539.
117. Chen Y, Guo Z, Parsons S, Sadler PJ. Stereospecific and kinetic control over the hydrolysis of a sterically hindered platinum picoline anticancer complexes. Chem Eur J 1998;4:672-676.
118. Chen Y, Guo Z, Parkinson JA, Sadler PJ. Kinetic control of reactions of a sterically hindered platinum picoline anticancer complex with guanosine 5′-monophosphate and glutathione. J Chem Soc Dalton Trans 1998;21:3577-3585.
119. Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR. In vitro circumvention of cisplatin-resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 1998;77:366-373.
120. Raynaud FI, Boxall FE, Goddard PM. cis-Amminedichloro(2-methylpyridine)platinum(II) (AMD473), a novel sterically hindered platinum complex: In vivo activity, toxicology, and pharmacokinetics in mice. Clin Cancer Res 1997;3:2063-2074.
121. Palmer BD, Lee HH, Johnson P, Baguley BC, Wicham G, Wakelin LPG, McFadyen WD, Denny WA. DNA-directed alkylating agents. 2. Synthesis and biological activity of platinum complexes linked to 9-anilinoacridine. J Med Chem 1990;22:3008-3014.
122. Lee HH, Palmer BD, Baguley BC, Chin M, McFadyen WD, Wickham G, Denny WA. DNA-directed alkylating agents. 5. Acridinecarboxamide derivatives of (1,2-diaminoethane)dichloroplatinum(II). J Med Chem 1992;35:2983-2987.
123. Murray V, Motyka H, England PR, Wickham G, lee HH, Denny WA, McFadyen WD. An investigation of the sequence-specific interaction of cis-diamminedichloroplatinum(II) and four analogues, including two acridine-tethered complexse, with DNA inside human cells. Biochemistry 1992;31:11812-11817.
124. Zunino F, Savi G, Pasini A. Synthesis and antitumor activity of a platinum(II)-doxorubicin complex. Cancer Chemother Pharmacol 1986;18:180-182.
125. Gust R, Niebler K, Schonenberger H. Investigation of the configurational and conformational influences on the hormonal activity of 1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamines and of their platinum(II) complexes. 1. Synthesis, estradiol receptor affinity, and estrogenic activity of diastereomeric [N-alkyl- and N,N′-dialkyl-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloro-platinum (II) complexes. J Med Chem 1995;38:2070-2079.
126. Apfelbaum HC, Blum J, Mandelbaumshavit F. Preparation and anticancer activity of two tryptamine derived platinum complexes. Inorg Chim Acta 1991;186:243-246.
127. Sachinvala ND, Chen H, Niemezura WP, Furusawa E, Cramer RE, Rupp JJ, Ganjan I. Synthesis, characterization, and anticancer activities of the first platinum complexes from sucrose. J Med Chem 1993;36:1791-1795.
128. Ho Y-P, To KKW, Au-Yeung SCF, Wang X, Lin G, Han X. Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety. J Med Chem 2001;44:2065-2068.
129. Cassileth BR. Alternative and complementary cancer treatments. Oncologists 1996;1:173-179.
130. Borchers AT, Hackman RM, Keen CL, Stern JS, Gershwin ME. Complementary medicine: A review of immunomodulatory effects of Chinese herbal medicines. Am J Clin Nutr 1997;66:1303-1312.
131. Wang GS. Medical uses of Mylabris in ancient China and recent studies. J Ethnopharm 1989;26:147-162.
132. Li YM, Casida JE. Cantharidin-binding protein: Identification as protein phosphatase 2A. Proc Natl Acad Sci USA 1992;89:11867-11870.
133. Graziano MJ, Waterhouse AL, Casida JE. Cantharidin poisoning associated with specific binding site in liver. Biochem Biophys Res Commun 1987;149:79-85.
134. Graziano MJ, Pessah IN, Matsuzawa M, Casida JE. Partial characterization of specific cantharidin binding sites in mouse tissues. Mol Pharmacol 1988;33:706-712.
135. Yi SN, Wass J, Vincent P, Iland H. Inhibitory effect of norcantharidn on K562 human myeloid leukemia cells in vitro. Leuk Res 1992;15:883-886.
136. Liu XH, Blazsek I, Quittet P, Comisso M, Anjo A, Wang GS, Misset JL. Effects of norcantharidin, a potent phosphatase type 2A inhibitor, on normal and malignant hematopoietic cell growth. Eur J Cancer 1995;31:953-963.
137. Simsiman GV, Daniel TC, Chesters G. Diquat and endothall: Their fates in the environment. Residue Rev 1976;62:131-174.
138. Blazsek I, Thiery JP, Anjo A, Reynes M, Legras S, Marion S, Jasmin C. Inhibitors of protein phosphatase type 2A are novel potential anticancer agents. Cancer Detection Prevention [Abstract] 1996;20:332A.
139. Thiery JP, Blazsek I, Legras S, Marion S, Reynes M, Anjo A, Adam R, Misset JL. Hepatocellular carcinoma cell lines from diethylnitrosamine phenobarbital-treated rats. Characterization and sensitivity to endothall, a protein serine/threonine phosphatase-2A inhibitor. Hepatology 1999;29:1406-1417.
140. Page JD, Husain I, Sancar A, Chaney SG. Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry 1990;29:1016-1024.
141. Schmidt W, Chaney SG. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 1993;53:799-805.
142. Bungo M, Fujiwara Y, Kasahara K, Nakagawa K, Ohe Y, Sasaki Y, Irino S, Saijo N. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human nonsmall cell lung cancer cell line. Br J Cancer 1990;62:72-77.
143. O'Dwyer PJ, Hamilton TC, Young RC, LaCreta FP, Carp N, Tew KD, Padavic K, Comis RL, Ozols RF. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoimine: Clinical and biochemical results. J Natl Cancer Inst 1992;84:264-267.
144. Ariza RR, Keyse SM, Moggs JG, Wood RD. Reversible protein phosphorylation modulates nucleotide excision repair of damaged DNA by human cell extracts. Nucleic Acids Res 1996;24:433-440.
145. Cohen P, Klumpp S, Schelling DL. An improved procedure for identifying and quantitating protein phosphatases in mammalian tissues. FEBS Lett 1989;250:596-600.
146. Zolnierowicz S. Type 2A protein phosphatase, the complex regulator of numerous signaling pathways. Biochem Pharmacol 2000;60:1225-1235.
147. Clarke PR, Hoffman I, Draetta G, Karsenti E. Dephosphorylation of cdc25-C by a type-2A protein phosphatase: Specific regulation during the cell cycle in Xenopus extracts. Mol Biol Cell 1993;4:397-411.
148. Sontag E, Fedorov S, Kambayashi C, Robbins D, Cobb M, Mumby M. The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation. Cell 1993;75:887-897.
149. Mayer-Jaekel RE, Ohkura H, Gomes R, Sunkel CE, Baumgartner S, Hemmings BA, Glover DM. The 55 kD regulatory subunit of Drosophila protein phosphatase 2A is required for anaphase. Cell 1993;72:621-633.
150. Lee TH. The role of protein phosphatase type-2A in the Xenopus cell cycle: Initiation of the G2/M transition. Semin Cancer Biol 1995;6:203-209.
151. Schonthal AH. Regulation of gene expression by serine/threonine protein phosphatases. Semin Cancer Biol 1995;6:239-248.
152. Wera S, Hemmings BA. Serine/threonine protein phosphatases. Biochem J 1995;311:17-29.
153. To KKW, Ho Y-P, Au-Yeung SCF. Determination of the release of hydrolyzed demethylcantharidin from novel traditional Chinese medicine-platinum compounds with anticancer activity by gas chromatography. J Chromatogr A 2002;947:319-326.